Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Deramiocel Claims

Capricor Therapeutics Faces Class Action Lawsuit Over Deramiocel Claims

Capricor Therapeutics, Inc. is currently facing significant legal challenges as a class action lawsuit is initiated against the company. The Gross Law Firm has reached out to shareholders who purchased Capricor shares between October 9, 2024, and July 10, 2025, urging them to consider joining the lawsuit. The allegations stem from claims that Capricor misled investors about the prospects of deramiocel, its lead drug candidate aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Specifically, the lawsuit alleges that Capricor presented overly optimistic expectations regarding its application for a Biologics License Application (BLA) to the FDA while failing to disclose critical adverse information about the drug’s safety and efficacy from the Phase 2 HOPE-2 trial.

On July 11, 2025, Capricor received a Complete Response Letter (CRL) from the FDA, which denied the BLA submission. The CRL cited insufficient evidence of the drug’s effectiveness and raised prominent concerns in the Chemistry, Manufacturing, and Controls sections. This development not only dashed hopes for the drug's approval but also triggered a dramatic decline in the company’s stock price, which fell from $11.40 per share on July 10 to $7.64 the day after the announcement. Such a steep drop highlights the potential impact of the allegations on investor confidence and the overall perception of Capricor's management practices.

The Gross Law Firm has emphasized its dedication to safeguarding investor rights and holding corporations accountable for their assertions. Shareholders who wish to participate in the class action lawsuit are encouraged to register by September 15, 2025, in order to receive updates on the case’s progression. Participation comes at no cost, presenting a potentially valuable opportunity for those affected by the stock's decline to seek redress for their losses. The firm’s outreach reflects a growing concern around corporate transparency and the necessity for companies in the biotechnology industry to provide accurate and comprehensive information regarding drug development and regulatory processes.

In parallel with these legal challenges, Capricor’s management faces increased scrutiny regarding its communication strategies and risk management practices. As the company navigates this turbulent period, stakeholders and potential investors will be closely monitoring developments in both the lawsuit and the regulatory landscape surrounding deramiocel. The outcome of this situation could have lasting implications not only for Capricor's future but also for investor trust in the biotech sector as a whole.